European Society of Cardiology - Heart Failure 2018
May 26 - 29, 2018
Levosimendan in acute and advanced heart failure
Webcast recordings from the European Society of Cardiology - Heart Failure 2018 Congress on Monday, 28 May
The use of inotropes for correcting haemodynamic dysfunction in patients with congestive heart failure has been described over many decades. However, negative or insufficient data has been collected on the effects of cardiac glycosides, catecholamines, and phosphodiesterase inhibitors on quality of life and survival. More recently, the calcium sensitiser and potassium channel opener levosimendan has been proposed as a safer inodilator.
This series of tutorials, listed below, focus on how to use safely and effectively levosimendan in acute and advanced heart failure.
Levosimendan and renal function: how to avoid kidney dysfunction in AHF?